Kadmon Pharmaceuticals won approval from the Food and Drug Administration on Friday to market a new treatment for chronic graft-versus-host disease — a debilitating immune condition that can affect as many as half of the blood cancer patients who undergo bone marrow transplants.
The newly approved drug, called Rezurock, is Kadmon’s first internally developed medicine to reach the market.
“The FDA has been remarkably wonderful to work with, I have to say, with all the noise about the FDA recently,” said Kadmon CEO Harlan Waksal. “We’re prepared for this approval, and we’ll have the drug rolled out in the next month.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
